Education
MTE, Managing the Technology Enterprise Program (2000), IMD, Lausanne
Ph.D. in Biomedical Engineering & Engineering Mechanics (1990) Iowa State University, Ames, Iowa.
MS in Biomedical Engineering (1987) Iowa State University, Ames, Iowa.
Diploma in Mechanical Engineering (1985) National Technical University of Athens.
Professional Activities
2002 - present: Professor and director of LHTC
2010 - present: Founder and director of Rheon Medical SA, Préverenges, Switzerland
2008 - present: Founder and director of Antlia S.A., PSE-C, EPFL campus, Switzerland
1998 - 2007: Founder and Scientific Director of EndoArt S.A., Lausanne, Switzerland
1996 - 2002: Assistant professor at the Biomedical Engineering Laboratory, Swiss Federal Institute of Technology, Lausanne, Switzerland.
1991 - 1996: Research Associate at Swiss Federal Institute of Technology - Lausanne
1990 - 1991: Lecturer, Iowa State University
Johan Auwerx is Professor at the École Polytechnique Fédérale in Lausanne, Switzerland, where he occupies the Nestle Chair in Energy Metabolism. Dr. Auwerx has been using molecular physiology and systems genetics to understand metabolism in health, aging and disease. Much of his work focused on understanding how diet, exercise and hormones control metabolism through changing the expression of genes by altering the activity of transcription factors and their associated cofactors. His work was instrumental for the development of agonists of nuclear receptors - a particular class of transcription factors - into drugs, which now are used to treat high blood lipid levels, fatty liver, and type 2 diabetes. Dr. Auwerx was amongst the first to recognize that transcriptional cofactors, which fine-tune the activity of transcription factors, act as energy sensors/effectors that influence metabolic homeostasis. His research validated these cofactors as novel targets to treat metabolic diseases, and spurred the clinical use of natural compounds, such as resveratrol, as modulators of these cofactor pathways.
Johan Auwerx was elected as a member of EMBO in 2003 and is the recipient of a dozen of international scientific prizes, including the Danone International Nutrition Award, the Oskar Minkowski Prize, and the Morgagni Gold Medal. His work is highly cited by his peers with a h-factor of over 100. He is an editorial board member of several journals, including Cell Metabolism, Molecular Systems Biology, The EMBO Journal, Journal of Cell Biology, Cell, and Science. Dr. Auwerx co-founded a handful of biotech companies, including Carex, PhytoDia, and most recently Mitobridge, and has served on several scientific advisory boards.
Dr. Auwerx received both his MD and PhD in Molecular Endocrinology at the Katholieke Universiteit in Leuven, Belgium. He was a post-doctoral research fellow in the Departments of Medicine and Genetics of the University of Washington in Seattle.
Patrick Aebischer a achevé une formation en Médecine (1980) et en Neurosciences (1983) aux Universités de Genève et de Fribourg en Suisse.
De 1984 à 1992, Patrick Aebischer a travaillé à Brown University (USA) au sein du Département des Neurosciences et au Département des Biomatériaux et des Organes Artificiels en tant que Professeur assistant, puis Professeur associé.
En 1992, Patrick Aebischer a été nommé Professeur de la Division Autonome de Recherche Chirurgicale et du Centre de Thérapie Génique (DARC) au Centre Hospitalier Universitaire Vaudois (CHUV) à Lausanne.
En 1999, Le Conseil Fédéral a nommé Patrick Aebischer en tant que Président de l'Ecole Polytechnique Fédérale de Lausanne (EPFL). Il a pris ses fonctions à la Présidence de lEPFL en mars 2000, position qu'il a occupée jusqu'au 31 décembre 2016.
Patrick Aebischer est membre de maintes sociétés professionnelles, tant en Europe quaux Etats-Unis.
Patrick Aebischer a fondé trois start-up de biotechnologies. Il siège au conseil d'administration de Lonza, de Logitech et de Nestlé. Il préside également l'advisory board du Novartis Venture Fund. Patrick Aebischer est membre du conseil de fondation du Festival de Jazz de Montreux, du Festival de Verbier et de la Fondation Jacobs.
Les recherches quil poursuit actuellement dans son laboratoire se concentrent sur le développement d'approches de thérapie cellulaire et de transfert génique pour le traitement des maladies neurodégénératives.
David Atienza Alonso is an associate professor of EE and director of the Embedded Systems Laboratory (ESL) at EPFL, Switzerland. He received his MSc and PhD degrees in computer science and engineering from UCM, Spain, and IMEC, Belgium, in 2001 and 2005, respectively. His research interests include system-level design methodologies for multi-processor system-on-chip (MPSoC) servers and edge AI architectures. Dr. Atienza has co-authored more than 350 papers, one book, and 12 patents in these previous areas. He has also received several recognitions and award, among them, the ICCAD 10-Year Retrospective Most Influential Paper Award in 2020, Design Automation Conference (DAC) Under-40 Innovators Award in 2018, the IEEE TCCPS Mid-Career Award in 2018, an ERC Consolidator Grant in 2016, the IEEE CEDA Early Career Award in 2013, the ACM SIGDA Outstanding New Faculty Award in 2012, and a Faculty Award from Sun Labs at Oracle in 2011. He has also earned two best paper awards at the VLSI-SoC 2009 and CST-HPCS 2012 conference, and five best paper award nominations at the DAC 2013, DATE 2013, WEHA-HPCS 2010, ICCAD 2006, and DAC 2004 conferences. He serves or has served as associate editor of IEEE Trans. on Computers (TC), IEEE Design & Test of Computers (D&T), IEEE Trans. on CAD (T-CAD), IEEE Transactions on Sustainable Computing (T-SUSC), and Elsevier Integration. He was the Technical Program Chair of DATE 2015 and General Chair of DATE 2017. He served as President of IEEE CEDA in the period 2018-2019 and was GOLD member of the Board of Governors of IEEE CASS from 2010 to 2012. He is a Distinguished Member of ACM and an IEEE Fellow.
Awards:
1999 Young Investigator Award Plenary Lectureship
, International Society for Neurochemistry
2011 Fellow
, ESMRMB
2011 Teaching Award
, Section Sciences de la Vie, EPFL
Cristina Cudalbu obtained her Bachelors of Science degree in Medical Physics in 2002 and Masters of Science degree in Biophysics and Medical Physics in 2003, both from University Babes-Bolyai, Cluj-Napoca, Romania. In 2006 she obtained her PhD degree in Localized Proton MRS and time domain quantification of cerebral metabolites at 7T and 4.7T at University Lyon 1, RMN Laboratory, Villeurbanne, France.In 2007, she joined, as a Scientist, the Laboratory for Functional and Metabolic Imaging at EPFL, where she implemented new acquisition and quantification techniques for in vivo nitrogen, proton and carbon MRS for preclinical studies. Starting 2012, Cristina Cudalbu was appointed as Research Staff Scientist and 9.4T MRI Operational Manager at Centre d’Imagerie Biomédicale (CIBM) at EPFL. She is now developing new research lines at CIBM, being oriented towards new acquisition and quantification techniques for in vivo proton, phosphorous, carbon, nitrogen MRS and fast MRSI, diffusion weighted spectroscopy and brain macromolecules quantification. She is now applying these developments on chronic hepatic encephalopathy, a research area that she developed at CIBM (https://actu.epfl.ch/news/when-liver-disease-affects-the-brain/), and on different collaborative projects with researchers from the five partner institutions of CIBM. 